Active substance
Rosuvastatin
- SFDA 74
- US FDA 31
- Health Canada 88
- US price lines 8
- NHS prices 12
- Safety 10
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| CRESCHOL 10 mg film-coated tablet | 10 mg | Film-coated tablet · Oral use | 30 Blister | SAR 61.30 | Generic · Prescription | Med City Pharma | Valid |
| CRESCHOL 20 mg film-coated tablet | 20 mg | Film-coated tablet · Oral use | 30 Blister | SAR 103.90 | Generic · Prescription | Med City Pharma | Valid |
| CRESCHOL 5 mg film-coated tablet | 5 mg | Film-coated tablet · Oral use | 30 Blister | SAR 34.00 | Generic · Prescription | Med City Pharma | Valid |
| CRESTOR 10 MG FILM COATED TABLETS | 10 mg | Film-coated tablet · Oral use | 28 Blister | SAR 77.25 | NCE · Prescription | AstraZeneca | Valid |
| CRESTOR 20 MG FILM COATED TABLETS | 20 mg | Film-coated tablet · Oral use | 28 Blister | SAR 130.65 | NCE · Prescription | AstraZeneca | Valid |
| CREVAST 10 mg film-coated tablet | 10 mg | Film-coated tablet · Oral use | 30 Blister | SAR 55.15 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| CREVAST 20 mg film-coated tablet | 20 mg | Film-coated tablet · Oral use | 30 Blister | SAR 93.50 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| CREVAST 40 mg film-coated tablet | 40 mg | Film-coated tablet · Oral use | 30 Blister | SAR 183.00 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| CREVAST 5 mg film-coated tablet | 5 mg | Film-coated tablet · Oral use | 30 Blister | SAR 30.60 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| Docrosa | 10 mg | Film-coated tablet · Oral use | 28 Blister | SAR 50.55 | Generic · Prescription | Doctors Pharmaceutical manufacturer | Valid |
| Docrosa | 20 mg | Film-coated tablet · Oral use | 28 Blister | SAR 85.70 | Generic · Prescription | Doctors Pharmaceutical manufacturer | Valid |
| Docrosa | 40 mg | Film-coated tablet · Oral use | 28 Blister | SAR 171.45 | Generic · Prescription | Doctors Pharmaceutical manufacturer | Valid |
| Docrosa | 5 mg | Film-coated tablet · Oral use | 28 Blister | SAR 25.25 | Generic · Prescription | Doctors Pharmaceutical manufacturer | Valid |
| IVARIN 10MG FILM COATED TABLET | 10 mg | Film-coated tablet · Oral use | 30 Blister | SAR 75.65 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| IVARIN 20MG FILM COATED TABLET | 20 mg | Film-coated tablet · Oral use | 30 Blister | SAR 128.30 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| IVARIN 40MG FILM COATED TABLET | 40 mg | Film-coated tablet · Oral use | 30 Blister | SAR 210.40 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| IVARIN 5MG FILM COATED TABLET | 5 mg | Film-coated tablet · Oral use | 30 Blister | SAR 37.80 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| Kolitarda | 20 mg | Film-coated tablet · Oral use | 30 Blister | SAR 87.25 | Generic · Prescription | ALPHA PHARMA INDUSTRY | Valid |
| Kolitarda | 10 mg | Film-coated tablet · Oral use | 30 Blister | SAR 51.45 | Generic · Prescription | ALPHA PHARMA INDUSTRY | Valid |
| RESOVA 10MG FILM COATED TABLETS | 10 mg | Film-coated tablet · Oral use | 30 Blister | SAR 68.10 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| RESOVA 20MG FILM COATED TABLETS | 20 mg | Film-coated tablet · Oral use | 30 Blister | SAR 115.45 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| ROSA | 20 mg | Film-coated tablet · Oral use | 30 Blister | SAR 70.00 | Generic · Prescription | BATTERJEE PHARMACETICAL FACTORY | Valid |
| ROSA | 10 mg | Film-coated tablet · Oral use | 30 Blister | SAR 45.00 | Generic · Prescription | BATTERJEE PHARMACETICAL FACTORY | Valid |
| ROST | 10 mg | Tablet · Oral use | 30 Blister | SAR 55.15 | Generic · Prescription | Saudi Amarox | Valid |
| ROST | 20 mg | Tablet · Oral use | 30 Blister | SAR 93.50 | Generic · Prescription | Saudi Amarox | Valid |
49 more — full table
Indications — CHI Daman Drug Formulary
ANTIPHOSPHOLIPID SYNDROME; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; ISCHEMIC STROKE; NON-ST WAVE ELEVATED MYOCARDIAL INFARCTION (NSTEMI); ST-WAVE ELEVATED MYOCARDIAL INFARCTION (STEMI)
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| CRESTOR | EQ 5MG BASE; EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | ASTRAZENECA | Prescription | 12 Aug 2003 |
| ROSUVASTATIN CALCIUM | EQ 5MG BASE; EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | WATSON LABS INC | Prescription | 29 Apr 2016 |
| ROSUVASTATIN CALCIUM | EQ 5MG BASE; EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | CHARTWELL RX | Prescription | 19 Jul 2016 |
| ROSUVASTATIN CALCIUM | EQ 5MG BASE; EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | AUROBINDO PHARMA LTD | Prescription | 19 Jul 2016 |
| ROSUVASTATIN CALCIUM | EQ 5MG BASE; EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | GLENMARK SPECLT | Prescription | 19 Jul 2016 |
| ROSUVASTATIN CALCIUM | EQ 5MG BASE; EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | TORRENT | Prescription | 31 Oct 2016 |
| ROSUVASTATIN CALCIUM | EQ 5MG BASE; EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | ACCORD HLTHCARE | Prescription | 31 Oct 2016 |
| ROSUVASTATIN CALCIUM | EQ 5MG BASE; EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | RENATA | Prescription | 31 Oct 2016 |
| ROSUVASTATIN CALCIUM | EQ 5MG BASE; EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | CHANGZHOU PHARM | Prescription | 31 Oct 2016 |
| ROSUVASTATIN CALCIUM | EQ 5MG BASE; EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | HETERO LABS LTD V | Prescription | 31 Oct 2016 |
| ROSUVASTATIN CALCIUM | EQ 5MG BASE; EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | BIOCON PHARMA | Prescription | 31 Oct 2016 |
| ROSUVASTATIN CALCIUM | EQ 5MG BASE; EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | CADILA PHARMS LTD | Prescription | 23 Nov 2016 |
| ROSUVASTATIN CALCIUM | EQ 5MG BASE; EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | ALKEM LABS LTD | Prescription | 21 Mar 2017 |
| ROSUVASTATIN CALCIUM | EQ 5MG BASE; EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | MSN | Prescription | 22 Nov 2017 |
| ROSUVASTATIN CALCIUM | EQ 5MG BASE; EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | ZHEJIANG JINGXIN | Prescription | 1 Mar 2019 |
| ROSUVASTATIN CALCIUM | EQ 5MG BASE; EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | UMEDICA | Prescription | 9 Apr 2019 |
| ROSUVASTATIN CALCIUM | EQ 5MG BASE; EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | SCIEGEN PHARMS | Prescription | 24 Apr 2019 |
| ROSUVASTATIN CALCIUM | EQ 5MG BASE; EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | SHANDONG | Prescription | 7 May 2019 |
| ROSUVASTATIN CALCIUM | EQ 5MG BASE; EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | ZHEJIANG YONGTAI | Prescription | 4 Nov 2019 |
| ROSUVASTATIN CALCIUM | EQ 5MG BASE; EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | SUNSHINE | Prescription | 1 Apr 2020 |
| ROSUVASTATIN CALCIUM | EQ 5MG BASE; EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | APOTEX | Discontinued | 19 Jul 2016 |
| ROSUVASTATIN CALCIUM | EQ 5MG BASE; EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | STRIDES PHARMA INTL | Discontinued | 19 Jul 2016 |
| ROSUVASTATIN CALCIUM | EQ 5MG BASE; EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | TEVA PHARMS USA | Discontinued | 19 Jul 2016 |
| ROSUVASTATIN CALCIUM | EQ 5MG BASE; EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | SUN PHARM | Discontinued | 19 Jul 2016 |
| ROSUVASTATIN CALCIUM | EQ 5MG BASE; EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | SANDOZ | Discontinued | 19 Jul 2016 |
6 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| ACH-ROSUVASTATIN | 02438917 | 5 MG | TABLET · ORAL | ACCORD HEALTHCARE INC |
| ACH-ROSUVASTATIN | 02438925 | 10 MG | TABLET · ORAL | ACCORD HEALTHCARE INC |
| ACH-ROSUVASTATIN | 02438933 | 20 MG | TABLET · ORAL | ACCORD HEALTHCARE INC |
| ACH-ROSUVASTATIN | 02438941 | 40 MG | TABLET · ORAL | ACCORD HEALTHCARE INC |
| AG-ROSUVASTATIN | 02500132 | 5 MG | TABLET · ORAL | ANGITA PHARMA INC. |
| AG-ROSUVASTATIN | 02500140 | 10 MG | TABLET · ORAL | ANGITA PHARMA INC. |
| AG-ROSUVASTATIN | 02500159 | 20 MG | TABLET · ORAL | ANGITA PHARMA INC. |
| AG-ROSUVASTATIN | 02500167 | 40 MG | TABLET · ORAL | ANGITA PHARMA INC. |
| APO-ROSUVASTATIN | 02337975 | 5 MG | TABLET · ORAL | APOTEX INC |
| APO-ROSUVASTATIN | 02337983 | 10 MG | TABLET · ORAL | APOTEX INC |
| APO-ROSUVASTATIN | 02337991 | 20 MG | TABLET · ORAL | APOTEX INC |
| APO-ROSUVASTATIN | 02338009 | 40 MG | TABLET · ORAL | APOTEX INC |
| AURO-ROSUVASTATIN | 02442574 | 5 MG | TABLET · ORAL | AURO PHARMA INC |
| AURO-ROSUVASTATIN | 02442582 | 10 MG | TABLET · ORAL | AURO PHARMA INC |
| AURO-ROSUVASTATIN | 02442590 | 20 MG | TABLET · ORAL | AURO PHARMA INC |
| AURO-ROSUVASTATIN | 02442604 | 40 MG | TABLET · ORAL | AURO PHARMA INC |
| BIO-ROSUVASTATIN | 02444968 | 5 MG | TABLET · ORAL | BIOMED PHARMA |
| BIO-ROSUVASTATIN | 02444976 | 10 MG | TABLET · ORAL | BIOMED PHARMA |
| BIO-ROSUVASTATIN | 02444984 | 20 MG | TABLET · ORAL | BIOMED PHARMA |
| BIO-ROSUVASTATIN | 02444992 | 40 MG | TABLET · ORAL | BIOMED PHARMA |
| CRESTOR - 10MG | 02247162 | 10 MG | TABLET · ORAL | ASTRAZENECA CANADA INC |
| CRESTOR - 20MG | 02247163 | 20 MG | TABLET · ORAL | ASTRAZENECA CANADA INC |
| CRESTOR - 40MG | 02247164 | 40 MG | TABLET · ORAL | ASTRAZENECA CANADA INC |
| CRESTOR - 5MG | 02265540 | 5 MG | TABLET · ORAL | ASTRAZENECA CANADA INC |
| JAMP ROSUVASTATIN TABLETS | 02498332 | 5 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
63 more — full table
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | CRESTOR 10 MG TABLET | $8.8111 | per EA | 23 Sep 2026 |
| US NADAC | CRESTOR 20 MG TABLET | $8.80624 | per EA | 23 Sep 2026 |
| US NADAC | CRESTOR 40 MG TABLET | $8.80663 | per EA | 23 Sep 2026 |
| US NADAC | CRESTOR 5 MG TABLET | $8.81421 | per EA | 23 Sep 2026 |
| US NADAC | ROSUVASTATIN CALCIUM 10 MG TAB | $0.03602 | per EA | 7 Oct 2026 |
| US NADAC | ROSUVASTATIN CALCIUM 20 MG TAB | $0.04539 | per EA | 7 Oct 2026 |
| US NADAC | ROSUVASTATIN CALCIUM 40 MG TAB | $0.06919 | per EA | 7 Oct 2026 |
| US NADAC | ROSUVASTATIN CALCIUM 5 MG TAB | $0.03215 | per EA | 7 Oct 2026 |
| NHS Drug Tariff | Rosuvastatin 10mg capsules | £9.54 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Rosuvastatin 10mg orodispersible tablets sugar free | £19.78 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Rosuvastatin 10mg tablets | £1.68 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Rosuvastatin 15mg tablets | £4.97 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Rosuvastatin 20mg capsules | £12.72 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Rosuvastatin 20mg tablets | £1.52 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Rosuvastatin 30mg tablets | £5.97 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Rosuvastatin 40mg capsules | £15.12 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Rosuvastatin 40mg tablets | £1.61 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Rosuvastatin 5mg capsules | £8.52 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Rosuvastatin 5mg orodispersible tablets sugar free | £16.64 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Rosuvastatin 5mg tablets | £1.36 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 23 Sep 2026 CRESTOR — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 12 Feb 2025 EZALLOR SPRINKLE — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - EMA PRAC 28 Nov 2024 PRAC signal: Tubulointerstitial nephritis
Action for MAH: update of the product information: No - US FDA 26 Aug 2024 ROSZET — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - EMA PRAC 11 Jul 2024 PRAC signal: Tubulointerstitial nephritis
Action for MAH: update of the product information: No - EMA PRAC 13 Jan 2023 PRAC signal: Myasthenia gravis
Action for MAH: update of the product information: Yes - EMA PRAC 7 Jul 2022 PRAC signal: Myasthenia gravis
Action for MAH: update of the product information: No - EMA PRAC 11 Feb 2021 PRAC signal: Bullous pemphigoid
Action for MAH: update of the product information: No - EMA PRAC 3 Sep 2020 PRAC signal: Bullous pemphigoid
Action for MAH: update of the product information: No - EMA PRAC 11 Jun 2015 PRAC signal: Lichenoid drug eruption
Action for MAH: update of the product information: No
Combinations containing Rosuvastatin
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.